Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
NOTV

NOTV - Inotiv, Inc. Stock Price, Fair Value and News

2.25USD+0.21 (+10.29%)Market Closed

Market Summary

NOTV
USD2.25+0.21
Market Closed
10.29%

NOTV Stock Price

View Fullscreen

NOTV RSI Chart

NOTV Valuation

Market Cap

58.4M

Price/Earnings (Trailing)

-0.82

Price/Sales (Trailing)

0.11

EV/EBITDA

1.42

Price/Free Cashflow

1.78

NOTV Price/Sales (Trailing)

NOTV Profitability

EBT Margin

-15.02%

Return on Equity

-34.41%

Return on Assets

-8.74%

Free Cashflow Yield

56.18%

NOTV Fundamentals

NOTV Revenue

Revenue (TTM)

552.7M

Rev. Growth (Yr)

-21.41%

Rev. Growth (Qtr)

-12.15%

NOTV Earnings

Earnings (TTM)

-71.3M

Earnings Growth (Yr)

-381.08%

Earnings Growth (Qtr)

-212.44%

Breaking Down NOTV Revenue

Last 7 days

34.7%

Last 30 days

30.8%

Last 90 days

-62.3%

Trailing 12 Months

-54.3%

How does NOTV drawdown profile look like?

NOTV Financial Health

Current Ratio

0.37

Debt/Equity

0

Debt/Cashflow

119.38

NOTV Investor Care

Shares Dilution (1Y)

0.82%

Diluted EPS (TTM)

-2.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024552.7M000
2023597.3M582.2M572.4M585.2M
2022277.5M427.3M547.7M586.2M
202168.2M75.3M89.6M155.9M
202054.6M59.5M60.5M65.4M
201933.0M36.5M43.6M49.1M
201823.0M23.2M26.3M29.6M
201722.7M23.5M24.2M23.4M
201621.4M20.3M20.4M21.7M
201524.0M24.1M22.7M21.7M
201423.2M23.7M24.6M24.2M
201324.7M23.1M22.1M22.5M
201231.1M29.8M28.2M26.5M
201131.0M32.1M33.1M32.6M
20100028.8M29.9M

Tracking the Latest Insider Buys and Sells of Inotiv, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 14, 2023
garrett michael
bought
14,145
2.829
5,000
chief commercial officer
Dec 14, 2023
beattie john gregory
bought
149,836
3.1238
47,966
chief operating officer
Oct 17, 2023
coelho mary theresa
acquired
-
-
12,911
-
Apr 01, 2023
landman david
acquired
-
-
25,822
-
Apr 01, 2023
brown nigel
acquired
-
-
25,822
-
Apr 01, 2023
neff r matthew
acquired
-
-
25,822
-
Apr 01, 2023
davis gregory cole
acquired
-
-
25,822
-
Apr 01, 2023
johnson richard allen
acquired
-
-
25,822
-
Mar 30, 2023
beraldi fernanda
acquired
-
-
2,500
former gen'l counsel & sec'y
Mar 14, 2023
sagartz john e
bought
25,041
4.91
5,100
chief strategy officer

1–10 of 50

Which funds bought or sold NOTV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
new
-
266,000
266,000
-%
Jul 05, 2024
THURSTON, SPRINGER, MILLER, HERD & TITAK, INC.
new
-
39,776
39,776
0.01%
May 20, 2024
Virtu Financial LLC
new
-
300,000
300,000
0.02%
May 16, 2024
COMERICA BANK
unchanged
-
29,080
43,760
-%
May 16, 2024
JANE STREET GROUP, LLC
added
168
818,687
935,665
-%
May 15, 2024
STATE STREET CORP
reduced
-2.3
488,699
744,237
-%
May 15, 2024
D. E. Shaw & Co., Inc.
new
-
1,620,340
1,620,340
-%
May 15, 2024
CITADEL ADVISORS LLC
added
211
823,715
923,227
-%
May 15, 2024
Walleye Capital LLC
new
-
360,331
360,331
-%
May 15, 2024
GOLDMAN SACHS GROUP INC
added
546
2,320,670
2,447,610
-%

1–10 of 41

Are Funds Buying or Selling NOTV?

Are funds buying NOTV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NOTV
No. of Funds

Unveiling Inotiv, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 03, 2024
jermyn street associates llc
4.89%
1,260,024
SC 13D/A
Feb 14, 2023
iszo capital lp
0%
0
SC 13G/A
Oct 06, 2022
jermyn street associates llc
5.4%
1,378,280
SC 13D/A
Sep 20, 2022
p2 capital partners, llc
2.8%
715,705
SC 13D/A
Jul 05, 2022
jermyn street associates llc
8.1%
2,077,422
SC 13D/A
Feb 14, 2022
iszo capital lp
5.3%
1,275,379
SC 13G/A
Feb 11, 2022
portolan capital management, llc
3.00%
728,395
SC 13G/A
Feb 10, 2022
renaissance technologies llc
2.12%
516,565
SC 13G/A

Recent SEC filings of Inotiv, Inc.

View All Filings
Date Filed Form Type Document
Jun 10, 2024
3
Insider Trading
Jun 04, 2024
8-K
Current Report
May 24, 2024
S-8 POS
Employee Benefits Plan
May 24, 2024
S-8 POS
Employee Benefits Plan
May 24, 2024
S-8 POS
Employee Benefits Plan
May 24, 2024
S-8 POS
Employee Benefits Plan
May 24, 2024
S-8
Employee Benefits Plan
May 16, 2024
10-Q/A
Quarterly Report
May 15, 2024
8-K
Current Report
May 15, 2024
10-Q
Quarterly Report

Peers (Alternatives to Inotiv, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
182.8B
23.7B
-6.73% 16.57%
41.53
7.7
-8.94% -35.91%
40.7B
3.7B
-4.14% -7.47%
46.98
10.93
8.57% 23.94%
38.6B
6.6B
-0.60% 10.90%
31.09
5.86
-6.38% -8.07%
16.0B
9.3B
3.80% 2.36%
18.92
1.72
-3.29% 6.68%
13.7B
2.0B
9.85% 84.47%
43.97
7
25.57% 21.62%
13.7B
1.2B
-0.89% 119.73%
-37.5
11.34
39.26% 33.08%
11.1B
4.1B
1.06% 3.32%
25.05
2.71
0.49% -10.45%
MID-CAP
8.6B
2.5B
10.04% -52.99%
-35.62
3.38
15.21% 53.51%
3.8B
603.7M
-2.42% -20.01%
-8.25
6.3
25.21% 30.68%
3.6B
929.2M
-3.35% -26.84%
2.3K
3.83
28.93% 111.61%
SMALL-CAP
828.7M
275.1M
4.05% 57.37%
-4.52
3.01
-13.93% -126.97%
94.1M
31.1M
14.78% -87.85%
-1.22
3.02
0.95% 19.75%
19.9M
9.0M
-13.98% -53.22%
-1.35
2.22
4.46% 45.80%
423.4K
5.5M
-14.00% -69.72%
-0.03
0.08
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

Inotiv, Inc. News

Latest updates
Defense World04 Jul 202411:25 am
InvestorPlace2 months ago

Inotiv, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q2
Revenue-12.2%119,035135,501140,740157,468151,463122,754150,466172,666140,31384,21130,07722,89218,75117,88515,77415,76516,01212,91814,78610,86110,103
Gross Profit-----------10,3317,6466,2805,8774,4475,0645,1933,4775,9263,129-
Operating Expenses-----------13,7399,3496,8015,8635,8185,5415,3884,4975,4213,379-
  S&GA Expenses1.0%5,4035,3485,0334,7934,7644,5014,4634,8024,6472,7381,1748388806255276921,447882876730-
  R&D Expenses-----------7.00107203196188105162162230128-
EBITDA Margin-67.0%0.03*0.10*-0.05*-0.47*-0.46*-0.46*-0.50*-0.08*-0.20*-0.46*0.16*0.03*---------
Interest Expenses-2.4%11,08811,36411,26810,78610,51510,4508,8888,4417,5474,828521449366347405382392311216178-
Income Taxes-82.1%-6,364-3,4941,480-2,380-2,466-15,974-9,5903426,846-12,785--4,75315.0033.0018.0021.0011.0097.002.00--
Earnings Before Taxes-181.8%-54,443-19,322-7,226-2,015-12,095-102,906-253,221-3,214182-96,1969,312-2,151-708-333-1,774-858-577-1,329292-426-
EBT Margin-116.1%-0.15*-0.07*-0.22*-0.64*-0.62*-0.61*-0.64*-0.21*-0.32*-0.58*0.07*-0.07*---------
Net Income-212.4%-48,079-15,388-9,6631,840-9,994-87,323-244,156-3,728-6,087-83,0479,3822,602-723-366-1,792-879-588-1,426290-426-
Net Income Margin-127.3%-0.13*-0.06*-0.18*-0.58*-0.58*-0.58*-0.62*0.03*0.04*0.07*0.12*0.00*---------
Free Cashflow358.5%16,918-6,54518,7633,69412,836-7,410171-9,4155,170-1,1432,6973,523---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.4%8158368578558698719631,1681,1391,00432217765.0063.0062.0064.0062.0061.0042.0039.0032.00
  Current Assets-5.2%18119121420321121323323522617418948.0018.0016.0015.0017.0016.0015.0012.0011.008.00
    Cash Equivalents48.6%33.0022.0035.0022.0025.0021.0019.0021.0047.0042.00139-2.001.001.003.000.001.001.001.001.00
  Inventory-10.3%45.0051.0056.0054.0064.0076.0071.0066.0057.0036.001.001.001.001.001.001.001.001.001.001.001.00
  Net PPE-0.1%19119219118918818818618715313348.0045.0029.0029.0029.0029.0028.0027.0023.0021.0018.00
  Goodwill0%94.0094.0094.0094.0094.0091.001586.004571.0052.0051.004.004.004.004.004.007.004.004.003.00
Liabilities4.6%60858158858059659160355452241321783.0057.0055.0054.0054.0052.0051.0031.0028.0021.00
  Current Liabilities350.2%49310913212113213616414613210755.0047.0036.0035.0032.0029.0029.0028.0017.0016.0012.00
  Long Term Debt-99.9%0.0037137037237036633133433225515429.0018.0017.0019.0021.0019.0019.0014.0012.009.00
    LT Debt, Current4422.1%3808.008.004.004.008.008.005.005.005.0010.0015.008.007.006.004.002.001.001.001.001.00
    LT Debt, Non Current-99.9%0.0037137037237036633133433225515429.0018.0017.0019.0021.0019.0019.0014.0012.009.00
Shareholder's Equity-18.5%20725426927627328036061461759010594.007.007.008.009.0010.0010.0011.0010.0010.00
  Retained Earnings-10.2%-517-469-453-444-444-435-348-104-101-94.43-11.01-20.40-23.00-22.28-21.91-20.12-19.24-18.65-17.10-17.39-16.96
  Additional Paid-In Capital0.3%71771571671471271070871571367911211027.0027.0027.0027.0026.0026.0025.0025.0025.00
Shares Outstanding0.4%26.0026.0026.0026.0026.0026.0026.0024.0023.0021.0016.0015.00---------
Minority Interest----0.66-0.73-1.31-1.00-0.61-0.14-0.24-0.62-----------
Float-----100---483---172---25.00---15.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations358.5%16,918-6,54518,7633,69412,836-7,410171-9,4155,170-1,1432,6973,5232,8741,652-2961,240-1,1061,4522106564.00
  Share Based Compensation-0.7%1,8841,8971,9882,0291,7812,0461,9171,9851,14119,15974658027918116017612381.0082.0072.0099.00
Cashflow From Investing-13.5%-4,587-4,043-7,699-4,492-8,406-8,158-15,595-14,506-71,228-232,393-5,006-46,629-951-1,474-1,037-1,743-1,255-6,096-2,348-3,583-1,534
Cashflow From Financing59.8%-1,173-2,921-310-1,042-1,16018,38413,989-1,36971,065119,466134,57365,580-892-429-2093,2532,0484,5492,2382,9131,327
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

NOTV Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Revenue$ 119,035$ 151,463$ 254,536$ 274,217
Costs and expenses:    
Selling5,4034,76410,7519,265
General and administrative19,79628,29339,72356,591
Depreciation and amortization of intangible assets14,15512,99028,40526,253
Other operating expense30,4404,81233,7598,451
Goodwill impairment loss00066,367
Operating loss(43,116)(2,125)(52,487)(92,703)
Other (expense) income:    
Interest expense(11,088)(10,515)(22,452)(20,965)
Other (expense) income(239)5451,174(1,333)
Loss before income taxes(54,443)(12,095)(73,765)(115,001)
Income tax benefit6,3642,4669,85818,440
Consolidated net loss(48,079)(9,629)(63,907)(96,561)
Less: Net income (loss) attributable to noncontrolling interests0365(440)756
Net loss attributable to common shareholders$ (48,079)$ (9,994)$ (63,467)$ (97,317)
Earnings Per Share [Abstract]    
Net loss attributable to common shareholders, basic (in dollars per share)$ (1.86)$ (0.39)$ (2.46)$ (3.79)
Net loss attributable to common shareholders, diluted (in dollar per share)$ (1.86)$ (0.39)$ (2.46)$ (3.79)
Weighted-average number of common shares outstanding:    
Basic (in shares)25,83125,68725,79725,645
Diluted (in shares)25,83125,68725,79725,645
Service    
Revenue$ 56,961$ 58,752$ 110,824$ 108,800
Costs and expenses:    
Cost of revenue (excluding depreciation and amortization of intangible assets)38,66336,80377,74070,804
Product    
Revenue62,07492,711143,712165,417
Costs and expenses:    
Cost of revenue (excluding depreciation and amortization of intangible assets)$ 53,694$ 65,926$ 116,645$ 129,189

NOTV Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Sep. 30, 2023
Current assets:  
Cash and cash equivalents$ 32,695$ 35,492
Trade receivables and contract assets, net of allowances for credit losses of $6,459 and $7,446, respectively65,75787,383
Inventories, net45,40656,102
Prepaid expenses and other current assets36,82133,408
Assets held for sale01,418
Total current assets180,679213,803
Property and equipment, net191,423191,068
Operating lease right-of-use assets, net46,79638,866
Goodwill94,28694,286
Other intangible assets, net291,331308,428
Other assets10,86310,079
Total assets815,378856,530
Current liabilities:  
Accounts payable28,38132,564
Accrued expenses and other current liabilities31,10225,776
Fees invoiced in advance41,67555,622
Current portion of long-term operating lease11,41310,282
Current portion of long-term debt380,3587,950
Total current liabilities492,929132,194
Long-term operating leases, net37,21829,614
Long-term debt, less current portion, net of debt issuance costs275369,795
Other long-term liabilities38,0556,373
Deferred tax liabilities, net39,73950,064
Total liabilities608,216588,040
Contingencies (Note 14)
Shareholders’ equity and noncontrolling interest:  
Authorized 74,000,000 shares at March 31, 2024 and September 30, 2023; 25,905,395 issued and outstanding at March 31, 2024 and 25,777,169 at September 30, 20236,4386,406
Additional paid-in capital717,139715,696
Accumulated deficit(517,185)(453,278)
Accumulated other comprehensive income770330
Total equity attributable to common shareholders207,162269,154
Noncontrolling interest0(664)
Total shareholders’ equity and noncontrolling interest207,162268,490
Total liabilities and shareholders’ equity and noncontrolling interest$ 815,378$ 856,530
NOTV
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment, Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services including, computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes, general and genetic toxicology, regulated bioanalysis, biotherapeutics, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes, nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
 CEO
 WEBSITEinotivco.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES2099

Inotiv, Inc. Frequently Asked Questions


What is the ticker symbol for Inotiv, Inc.? What does NOTV stand for in stocks?

NOTV is the stock ticker symbol of Inotiv, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inotiv, Inc. (NOTV)?

As of Fri Jul 12 2024, market cap of Inotiv, Inc. is 58.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NOTV stock?

You can check NOTV's fair value in chart for subscribers.

What is the fair value of NOTV stock?

You can check NOTV's fair value in chart for subscribers. The fair value of Inotiv, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inotiv, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NOTV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inotiv, Inc. a good stock to buy?

The fair value guage provides a quick view whether NOTV is over valued or under valued. Whether Inotiv, Inc. is cheap or expensive depends on the assumptions which impact Inotiv, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NOTV.

What is Inotiv, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 12 2024, NOTV's PE ratio (Price to Earnings) is -0.82 and Price to Sales (PS) ratio is 0.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NOTV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inotiv, Inc.'s stock?

In the past 10 years, Inotiv, Inc. has provided -0.009 (multiply by 100 for percentage) rate of return.